Denmark's Leo Pharma enters development agreement with Foamix  

2005.11.30
Leo Pharma has entered an agreement with Foamix, an Israeli technology company, to jointly develop two medicated foams for the treatment of psoriasis

Leo Pharma has entered an agreement with Foamix, an Israeli technology company, to jointly develop two medicated foams for the treatment of psoriasis. The foams will be based on Leo Pharma's proprietary Calcipotriene compound and its combination with specific steroids. The agreement includes significant milestone payments to Foamix.

Ernst Lunding, managing director of Leo Pharma says: "We believe that Foamix' foam offers the perfect properties to be able to deliver our anti-psoriasis actives. The foam spreads easily over large surfaces, absorbs instantly, doesn't burn and can deliver the active agents necessary to effectively treat psoriasis".

Nearly 13 million people worldwide suffer from psoriasis of whom 7 million are in the US, where between 150,000 to 260,000 new cases occur annually. Psoriasis affects men and women equally. The news was reported by financial daily newspaper Børsen.

Leo Pharma is headquartered in Ballerup near Copenhagen and employs 3,200 people in more than 40 countries. The pharmaceutical company is one of the world's leaders in dermatology and parenteral treatment of thromboembolic disorders.

Link > Leo Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×